Quantcast

Latest Typical antipsychotic Stories

2009-01-07 17:12:00

INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults. Lilly is continuing to work with the agency on the new drug application (NDA). The FDA does not require any additional clinical trials for the continued review of the NDA. Per the agency's...

2008-12-10 07:30:00

Results of Two Trials Identify Potential Initiation Dosing Regimen TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study presented today (1). Statistical significance was evidenced at all doses tested (25, 100, and 150 mg equivalent [eq.a]), when given every 4 weeks with a 150 mg eq. initiation dose. A separate...

2008-10-21 09:00:54

INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S. marketing and promotional practices for its antipsychotic medication Zyprexa(R) (olanzapine). As a result, the company will record in the third quarter of 2008 a charge of $1.415 billion, or $1.29 per share. The Government's...

2008-10-09 18:00:12

Alkermes, Inc. (NASDAQ: ALKS) today announced that patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ((risperidone) Long-Acting Injection). The U.S. Food and Drug Administration (FDA) has approved a new injection site, the deltoid muscle in the arm, for RISPERDAL CONSTA for the treatment of patients with schizophrenia. RISPERDAL CONSTA was previously approved as a gluteal injection only. "RISPERDAL CONSTA serves an important role in the treatment of...

2008-10-07 09:00:55

INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine). "We believe all of the parties involved share an interest in putting this dispute behind us," said Robert A. Armitage, Lilly's senior vice president and general counsel. "From our standpoint, it's...

2008-09-26 06:00:12

INDIANAPOLIS, Sept. 26 /PRNewswire-FirstCall/ -- The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Olanzapine Long-acting Injection (LAI), known in Europe by the trade name Zypadhera(TM), for maintenance treatment of adult patients with schizophrenia sufficiently stabilized during acute treatment with oral olanzapine, Eli Lilly and Company (LLY) announced today. The CHMP's positive opinion is now referred for final action to the European...

2008-09-02 09:00:07

BARCELONA, Spain, Sept. 2 /PRNewswire-FirstCall/ -- Final results from a 24-week study presented today at a major medical meeting in Barcelona suggest that investigational olanzapine long-acting injection (LAI) therapeutic doses showed a maintenance of treatment benefit for up to six months. A review of pooled safety data from all olanzapine LAI clinical trials was also presented at the meeting. Olanzapine LAI is an investigational formulation that combines Zyprexa(R) (olanzapine), an...

2008-07-01 18:00:05

WILMINGTON, Del., July 1 /PRNewswire-FirstCall/ -- AstraZeneca today announced that the US District Court for the District of New Jersey has granted the company's Motion for Summary Judgment of No Inequitable Conduct. AstraZeneca had sued Teva Pharmaceutical Industries Ltd. and Sandoz, Inc. alleging infringement of AstraZeneca's patent as a result of Teva's and Sandoz's filings of Abbreviated New Drug Applications (ANDAs). The ANDAs sought approval to market generic versions of SEROQUEL(R)...

2007-05-22 15:00:49

SAN DIEGO, May 22 /PRNewswire/ -- After administration of paliperidone extended-release (ER) tablets, blood levels of the drug were not affected when given with a common antidepressant, according to new data presented today at the 160th Annual Meeting of the American Psychiatric Association. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), is an antidepressant known to interact with several antipsychotic medications. This new study showed there was no clinically significant...

2005-12-30 13:40:00

NEW YORK (Reuters Health) - High levels of sugar in the blood, also known as hyperglycemia, is a common finding in individuals taking atypical antipsychotics who are thought to have normal blood sugar levels. Over a 2-year period, Dr. Michael J. Sernyak, of the VA Connecticut Healthcare System, New Haven, Connecticut, and colleagues examined the frequency of undiagnosed high blood sugar in 647 patients taking atypical antipsychotics, including Clozaril (clozapine), Risperdal (risperidone),...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related